I just listened to the conference call. Kim continued to state that they are in discussions with big pharma
for another partnership. The big question is when will the next one be announced. He telegraphed the answer during the call. Right near the end he said that he looks forward to the coming "months and weeks" ahead.
If he did not think a deal would close before the end of the year, he would have simply said "months". But
I think he tipped off that there will be another announcement within weeks. My guess is after Thanksgiving,
the first or second week in December. Gives investors more time to add to their positions as this will
likely trade under $2 until the next announcement. Did others who listened get that sense as well?
Will this week be the catalyst for Inovio' s "epic" run to becoming one of the next groundbreaking biotech companies? Will there be any new developments announced on Monday or Tuesday?
Will this be the day of the next big INO announcement? It would be prior to the Inovio presentations on the 3rd and 4th. Kim would love to discuss the good news at these conferences.
INO is up a little today. Markets in general are up so not surprised. What is surprising is the increase in volume on a Friday...could be the busiest day of this week. I think this is a great sign for next week and a potential turning point to build the next base as speculation regarding next announcement circulates. So far, anticipation of the next catalyst serves as the driver of the share price.
Prediction for next week and beyond: volume and volatility increase and pps tries to hold next level between
$2.30 and $2.50.
Shorts controlled the first two hours and dropped this down to $5.80. They are now covering and some are taking long positions. This is shown by less volatility the past 45 minutes. The more likely scenario for rest of day is a push to just beyond $8 and then will close around $7.50. Once shorts are done, they will let this one rip...give it another hour or so.
Keep in mind that the market cap is only $32M and the recent news is extremely positive. In general, the biotech sector is getting hammered so institutions are looking for something positive.
This has an ACAD like feel to it and $20 is now more likely than $2.
Let me know if others see the same as me or perhaps something different happening.
I still believe that INO will follow a similar path as ACAD, which was as low as $1.80 last November and is quickly approaching $30. ONCS uses same technology as INO and is a bargain at 27 cents.
All I care about is results...so far, so good. Think about how many smooth talking CEOs have not delivered. I am listening for his passion and commitment to shareholders. Certainly, the proof is in the pudding. The recent Roche deal is an example and I believe there will be more partnerships.
A slow, steady climb is best for INO. Keeps the traders away...until the next catalyst. Hopefully, the next major announcement hits when this is well over $2.
I still believe that it is a matter of days, not weeks, until the next bit of great news. Strategically, Kim would love to talk about at the upcoming conferences. Keep in mind that Kim plans to be at each one. It would be a great opportunity to talk about a new partnership during that time.
On August 2nd, INO closed above $2.00 for the first time in four years. The feeling at that time was that $3 was just weeks away with an anticipated partnership announcement and several opportunities for the company to impress at investor conferences in September.
Now, almost 3 months later, the stock is struggling to hold above $2. The Roche partnership was announced and Kim talked excitedly about Inovio' s future.
Do you feel that the stock is being manipulated or that investors are not overly thrilled with the company's potential for success? This has been a frustrating time for investors like me who expected more from the company at this point. Are others feeling the same ? What is the next likely catalyst?
The market basically sold off on the announcement. You did not mention the run up since July and that was based on an expected partnership announcement. So, a classic case of buy the rumor, sell the news. It's worth noting that INO does not trade like a speculative stock anymore, as evidenced by the recent tight daily trading ranges. It's becoming less of a trading stock and more like an investment.
Sure, it's been disappointing that the price has fallen back but, unlike other small biotechs we are not seeing wide swings. The model we want it to follow is ACAD--$2 a year ago and now trading at 12x. Review the pps for Acadia and ask if you think possible with Inovio...hmmm.
Today's volume was the highest for the week. Last time this happened on a Friday was Sep. 6th. On Monday the 9th the volume doubled and the Roche deal was announced on Tuesday the 10th. Perhaps something new is about to be announced next week. If not, I see this moving up in anticipation of next catalyst.
You are a non entity. ..unimportant. Admittedly, your postings, like everyone else on this board, have
No bearing on the stock price.
SWER is not legit. Would not get too excited about them.
I don't claim to be a daily trading expert. The entire market was hit hard today and never rebounded.
I rode ACAD from $5 to $20...sold to buy INO and rode that from $1 to $2.50 and sold. Put profits into OXBT and waiting for next run unless there is major pullback in INO next Tuesday.
I don't have any credibility in day to day predictions (like most people). But longer term I've done quite well...
From here, the bashers aren't going to short the stock...there is just not that much money to be made. The other strategy is to bash and hope for reduced share price...that could happen. But the bottom line is that
longs and bashers believe that the price will go up at some point. The mere presence of bashers exudes
a renewed confidence in INO.
English is his second language and he actually has great command of it and a strong vocabulary. Have you heard other CEOs present? And, remember, actions speak louder than words.
I do agree, however, that the response would be more positive from the investor conferences. According
to investor relations, these analysts are likely waiting for more clinical results before making the
investment in Inovio. Share volume needs to be strong to provide liquidity as well.